Loading...
XSTO
SUS
Market cap766mUSD
May 30, Last price  
143.90SEK
1D
-0.35%
1Q
-8.63%
IPO
1,184.82%
Name

Surgical Science Sweden AB

Chart & Performance

D1W1MN
P/E
55.78
P/S
8.31
EPS
2.58
Div Yield, %
—
Shrs. gr., 5y
15.60%
Rev. gr., 5y
54.17%
Revenues
884m
+0.14%
41,103,21446,100,00051,800,00057,976,00065,700,000101,515,000104,799,000366,778,000802,540,000882,853,000884,087,000
Net income
132m
-43.73%
-3,036,8581,600,0003,300,000-2,258,000-4,519,00012,598,00015,606,00086,248,000187,974,000233,972,000131,646,000
CFO
137m
-42.41%
07,500,00013,400,0007,937,0006,878,00055,202,00023,225,00039,083,000129,487,000238,291,000137,225,000
Earnings
Aug 20, 2025

Profile

Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence-based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim ST develops to train surgical technologists and surgical assistants; and LapSim essence, a portable and ready-to-use VR simulator. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach; simbionix simulators; and robotic surgery simulators. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.
URL
https://surgicalscience.com/
IPO date
Jun 19, 2017
Employees
259
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
884,087
0.14%
882,853
10.01%
802,540
118.81%
Cost of revenue
734,678
691,642
645,684
Unusual Expense (Income)
NOPBT
149,409
191,211
156,856
NOPBT Margin
16.90%
21.66%
19.54%
Operating Taxes
26,446
34,292
20,199
Tax Rate
17.70%
17.93%
12.88%
NOPAT
122,963
156,919
136,657
Net income
131,646
-43.73%
233,972
24.47%
187,974
117.95%
Dividends
Dividend yield
Proceeds from repurchase of equity
19,148
BB yield
Debt
Debt current
15,079
Long-term debt
235,408
80,046
29,364
Deferred revenue
20,288
Other long-term liabilities
138,313
17,209
41,015
Net debt
(732,747)
(559,090)
(393,657)
Cash flow
Cash from operating activities
137,225
238,291
129,487
CAPEX
(6,104)
(10,456)
(34,548)
Cash from investing activities
(47,530)
(44,129)
(34,548)
Cash from financing activities
227,653
15,847
17,093
FCF
70,426
80,551
102,528
Balance
Cash
968,155
634,366
433,733
Long term investments
4,770
4,367
Excess cash
923,951
594,993
397,973
Stockholders' equity
641,960
947,091
857,466
Invested Capital
4,560,399
3,827,739
3,895,357
ROIC
2.93%
4.06%
3.70%
ROCE
2.87%
4.28%
3.61%
EV
Common stock shares outstanding
50,941
50,914
Price
Market cap
EV
EBITDA
149,409
246,824
208,441
EV/EBITDA
Interest
656
1,305
Interest/NOPBT
0.34%
0.83%